Savara Inc (YB4P F) stock market data APIs
€5.3656
-0.12(-2.2%)
as of January 22, 2026
Try our APIs with
free plan!
Savara Inc Financial Data Overview
Price chart is built with
Anychart
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company was founded in 2007 and is headquartered in Langhorne, Pennsylvania.
Prev. Close
5.3656
Open
5.2456
High
5.4042
Low
5.2248
52 wk Range
1.66-5.9
Market Cap
1 099 M
Shares Outstanding
203 M
Revenue
1 000
EPS
-0.14
Beta
0.276
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Savara Inc data using free add-ons & libraries
Get Savara Inc Fundamental Data
Savara Inc Fundamental data includes:
- Net Revenue: 1 000
- EBITDA: -120 388 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-14
- EPS/Forecast: -0.12
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Savara Inc News
New
Savara Announces New Employment Inducement Grant
AUSTIN, Texas, August 04, 2023--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement aw...
Savara Announces Pricing of $80 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
LANGHORNE, Pa., July 13, 2023--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the pricing of an underwrit...
Savara Added to Russell 3000® Index
AUSTIN, Texas, June 26, 2023--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that it has been added to th...
Savara Completes Enrollment of Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Target Enrollment was 160 Patients, IMPALA-2 Enrolled 164 Patients Company Remains On-Track to Report Top Line Data by End of 2Q 2024 AUSTIN, Texas, June 26, 2023--(BUSINESS WIRE)--Savara Inc. (Nasd...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
